Pharmacoeconomics And Outcomes Research at Hochschule Fresenius | Flashcards & Summaries

Select your language

Suggested languages for you:
Log In Start studying!

Lernmaterialien für Pharmacoeconomics and Outcomes Research an der Hochschule Fresenius

Greife auf kostenlose Karteikarten, Zusammenfassungen, Übungsaufgaben und Altklausuren für deinen Pharmacoeconomics and Outcomes Research Kurs an der Hochschule Fresenius zu.

TESTE DEIN WISSEN

Summary of healthcare evaluation:

Lösung anzeigen
TESTE DEIN WISSEN
  • Economic evaluation is used in healthcare to ensure that the addition on new interventions does not displace more health than is gained.


  • To achieve this we need to:
    • Compare costs of the intervention and comparator (incremental costs)
    • Compare benefits of the intervention and comparator (incremental benefits)
    • Calculate the ICER or INB
    • Use the appropriate decision-rule


  • Uncertainty can be incorporated into the results using sensitivity analysis
Lösung ausblenden
TESTE DEIN WISSEN

Definition of:

Cost of illness

Lösung anzeigen
TESTE DEIN WISSEN
  • Assessment of all costs associated with an illness such as cost of treatment, cost of care, travel time, productivity loss
  • Cannot lead to recommendations or a decision
  • Can be used to assess the economic burden put on society by a certain condition
  • Can be an argument to put more research resources or more attention to a condition (Advocacy)
Lösung ausblenden
TESTE DEIN WISSEN

Definition of indirect costs in healthcare:

Lösung anzeigen
TESTE DEIN WISSEN

Costs suffered as a result of ill health or benefits in terms of productivity loss or gain.

Lösung ausblenden
TESTE DEIN WISSEN

Definition of intangible (morbidity) costs in healthcare

Lösung anzeigen
TESTE DEIN WISSEN

These were initially considered as those costs due to disease consequences such as pain that are not easy to measured and value. Willingness to pay method are able to value “intangible” costs in monetary terms.

Lösung ausblenden
TESTE DEIN WISSEN

Definition of: 

Time Horizon

Lösung anzeigen
TESTE DEIN WISSEN


how long to measure costs and consequences

  • long enough into the future to capture important differences
    • Disease profile i.e. acute or chronic disease
    • Cost category considered e.g. those within or outside healthcare sector
    • Outcome consideration e.g. intervention removing environmental toxins can have outcomes extending beyond generations


For time horizon beyond 12 months, both costs and consequences must be discounted to show the present value.

Lösung ausblenden
TESTE DEIN WISSEN

Definition of: 

Cost analysis

Lösung anzeigen
TESTE DEIN WISSEN
  • Plain evaluation of the costs associated with the intervention under investigation
  • Cannot lead to recommendations or a decision**
  • Can give an idea about the costs of the intervention as part of a health economic evaluation or as a starting point for further research
Lösung ausblenden
TESTE DEIN WISSEN

Definition of: 

  • Technical efficiency
  • Allocative efficiency
Lösung anzeigen
TESTE DEIN WISSEN

Technical efficiency 

When considering how to produce any particular good or service, the aim is to achieve the maximum output from available resources, or for a given output, use the least resources possible.



Allocative efficiency

Once goods and services have been produced, the aim is to allocate these to those individuals who will derive the maximum benefit from consuming the goods or service.

Lösung ausblenden
TESTE DEIN WISSEN

Objective of healthcare is to improve population HEALTH

What is health?

Lösung anzeigen
TESTE DEIN WISSEN

“A state of complete physical, mental, and social well-being and not just merely the absence of disease of infirmity”-WHO, 1948

  • Descriptive state of health
Lösung ausblenden
TESTE DEIN WISSEN

Different Perspectives in Economic Evaluation

Lösung anzeigen
TESTE DEIN WISSEN
  • Individual patients :
    • All patient borne costs
  • Third party payer: Healthcare perspective 
    • Health provider resources only [e.g. Staff costs, prescribed drugs], Insurer, Reimbursements
  • Healthcare and individual patients
    • Patient borne costs and healthcare costs [Patient travel expenses, OTC medicines, hospital costs]
  • Societal perspective 
    • Includes different players in society [e.g. Carer time] and other sector costs [e.g. social costs for time off from work]
Lösung ausblenden
TESTE DEIN WISSEN

Points of Measuring outcomes

Depending on the typ of analysis

Lösung anzeigen
TESTE DEIN WISSEN
  • CEA
    • Depends on the objectives of the intervention under investigation
    • Final vs. intermediate/ surrogate outcomes
  • CUA
    • Utilities/ Preferences in combination with lifetime
    • Different methods of measurement
  • CBA
    • Preferences in health states are converted into monetary units
    • Different methods of measurement
Lösung ausblenden
TESTE DEIN WISSEN

Measuring outcomes in CEA

Lösung anzeigen
TESTE DEIN WISSEN
  • Tends to use clinical outcomes and single dimension reported in their natural units
  • This is appropriate with a major objectives of the therapy 
    • cost per life years gained.
    • Can compare therapies within the medical field
  • Other measures include disease specific outcomes such as symptom free days
    • There must a clear link between intermediate outcome and end point
Lösung ausblenden
TESTE DEIN WISSEN

Points of: "Why Economic Evaluation?" 

Lösung anzeigen
TESTE DEIN WISSEN
  • Resources are scarce, need to make choices and minimise opportunity cost.
  • To identify clearly the relevant alternatives.
  • Lets us consider different perspectives of the analysis
  • Allows for quantification of the magnitude of changes in costs and outcomes for competing interventions.
  • Increases the explicitness and accountability in decision-making.
  • Can be Primary or secondary research
Lösung ausblenden
  • 196466 Karteikarten
  • 3545 Studierende
  • 63 Lernmaterialien

Beispielhafte Karteikarten für deinen Pharmacoeconomics and Outcomes Research Kurs an der Hochschule Fresenius - von Kommilitonen auf StudySmarter erstellt!

Q:

Summary of healthcare evaluation:

A:
  • Economic evaluation is used in healthcare to ensure that the addition on new interventions does not displace more health than is gained.


  • To achieve this we need to:
    • Compare costs of the intervention and comparator (incremental costs)
    • Compare benefits of the intervention and comparator (incremental benefits)
    • Calculate the ICER or INB
    • Use the appropriate decision-rule


  • Uncertainty can be incorporated into the results using sensitivity analysis
Q:

Definition of:

Cost of illness

A:
  • Assessment of all costs associated with an illness such as cost of treatment, cost of care, travel time, productivity loss
  • Cannot lead to recommendations or a decision
  • Can be used to assess the economic burden put on society by a certain condition
  • Can be an argument to put more research resources or more attention to a condition (Advocacy)
Q:

Definition of indirect costs in healthcare:

A:

Costs suffered as a result of ill health or benefits in terms of productivity loss or gain.

Q:

Definition of intangible (morbidity) costs in healthcare

A:

These were initially considered as those costs due to disease consequences such as pain that are not easy to measured and value. Willingness to pay method are able to value “intangible” costs in monetary terms.

Q:

Definition of: 

Time Horizon

A:


how long to measure costs and consequences

  • long enough into the future to capture important differences
    • Disease profile i.e. acute or chronic disease
    • Cost category considered e.g. those within or outside healthcare sector
    • Outcome consideration e.g. intervention removing environmental toxins can have outcomes extending beyond generations


For time horizon beyond 12 months, both costs and consequences must be discounted to show the present value.

Mehr Karteikarten anzeigen
Q:

Definition of: 

Cost analysis

A:
  • Plain evaluation of the costs associated with the intervention under investigation
  • Cannot lead to recommendations or a decision**
  • Can give an idea about the costs of the intervention as part of a health economic evaluation or as a starting point for further research
Q:

Definition of: 

  • Technical efficiency
  • Allocative efficiency
A:

Technical efficiency 

When considering how to produce any particular good or service, the aim is to achieve the maximum output from available resources, or for a given output, use the least resources possible.



Allocative efficiency

Once goods and services have been produced, the aim is to allocate these to those individuals who will derive the maximum benefit from consuming the goods or service.

Q:

Objective of healthcare is to improve population HEALTH

What is health?

A:

“A state of complete physical, mental, and social well-being and not just merely the absence of disease of infirmity”-WHO, 1948

  • Descriptive state of health
Q:

Different Perspectives in Economic Evaluation

A:
  • Individual patients :
    • All patient borne costs
  • Third party payer: Healthcare perspective 
    • Health provider resources only [e.g. Staff costs, prescribed drugs], Insurer, Reimbursements
  • Healthcare and individual patients
    • Patient borne costs and healthcare costs [Patient travel expenses, OTC medicines, hospital costs]
  • Societal perspective 
    • Includes different players in society [e.g. Carer time] and other sector costs [e.g. social costs for time off from work]
Q:

Points of Measuring outcomes

Depending on the typ of analysis

A:
  • CEA
    • Depends on the objectives of the intervention under investigation
    • Final vs. intermediate/ surrogate outcomes
  • CUA
    • Utilities/ Preferences in combination with lifetime
    • Different methods of measurement
  • CBA
    • Preferences in health states are converted into monetary units
    • Different methods of measurement
Q:

Measuring outcomes in CEA

A:
  • Tends to use clinical outcomes and single dimension reported in their natural units
  • This is appropriate with a major objectives of the therapy 
    • cost per life years gained.
    • Can compare therapies within the medical field
  • Other measures include disease specific outcomes such as symptom free days
    • There must a clear link between intermediate outcome and end point
Q:

Points of: "Why Economic Evaluation?" 

A:
  • Resources are scarce, need to make choices and minimise opportunity cost.
  • To identify clearly the relevant alternatives.
  • Lets us consider different perspectives of the analysis
  • Allows for quantification of the magnitude of changes in costs and outcomes for competing interventions.
  • Increases the explicitness and accountability in decision-making.
  • Can be Primary or secondary research
Pharmacoeconomics and Outcomes Research

Erstelle und finde Lernmaterialien auf StudySmarter.

Greife kostenlos auf tausende geteilte Karteikarten, Zusammenfassungen, Altklausuren und mehr zu.

Jetzt loslegen

Das sind die beliebtesten StudySmarter Kurse für deinen Studiengang Pharmacoeconomics and Outcomes Research an der Hochschule Fresenius

Für deinen Studiengang Pharmacoeconomics and Outcomes Research an der Hochschule Fresenius gibt es bereits viele Kurse, die von deinen Kommilitonen auf StudySmarter erstellt wurden. Karteikarten, Zusammenfassungen, Altklausuren, Übungsaufgaben und mehr warten auf dich!

Das sind die beliebtesten Pharmacoeconomics and Outcomes Research Kurse im gesamten StudySmarter Universum

Marcoeconomics

FHNW - Fachhochschule Nordwestschweiz

Zum Kurs
Nutrigenomics and pharmacogenomics

Universidad de San Pablo CEU

Zum Kurs
Legal Pharmacy and Ethics

Davao Doctors College

Zum Kurs
Research and methods

University of Amsterdam

Zum Kurs

Die all-in-one Lernapp für Studierende

Greife auf Millionen geteilter Lernmaterialien der StudySmarter Community zu
Kostenlos anmelden Pharmacoeconomics and Outcomes Research
Erstelle Karteikarten und Zusammenfassungen mit den StudySmarter Tools
Kostenlos loslegen Pharmacoeconomics and Outcomes Research